{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:07:25Z","timestamp":1787501245991,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1124\/dmd.115.068601","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T22:54:11Z","timestamp":1457477651000},"page":"781-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data"],"prefix":"10.1016","volume":"44","author":[{"given":"Hoa Q.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Callegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.115.068601_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0731-7085(91)80246-6","article-title":"Solubility and acid-base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software","volume":"9","author":"Andersin","year":"1991","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.115.068601_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/tx8004086","article-title":"Predicting circulating human metabolites: how good are we?","volume":"22","author":"Anderson","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.115.068601_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/taap.2002.9440","article-title":"Drug metabolites in safety testing","volume":"182","author":"Baillie","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.115.068601_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(95)91209-6","article-title":"Prolonged sedation due to accumulation of conjugated metabolites of midazolam","volume":"346","author":"Bauer","year":"1995","journal-title":"Lancet"},{"key":"10.1124\/dmd.115.068601_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1029\/2000WR900350","article-title":"Practical identifiability analysis of large environmental simulation models","volume":"37","author":"Brun","year":"2001","journal-title":"Water Resour Res"},{"key":"10.1124\/dmd.115.068601_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.114.059311","article-title":"Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone","volume":"43","author":"Chen","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.1988.tb03330.x","article-title":"Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration","volume":"25","author":"Clausen","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib11","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1983.tb02271.x","article-title":"Relationship between plasma concentration and effect of midazolam after oral and intravenous administration","volume":"16","author":"Crevoisier","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0090-9556(25)06608-5","article-title":"Effect of diffusional barriers on drug and metabolite kinetics","volume":"15","author":"de Lannoy","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib62","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1124\/dmd.113.054031","article-title":"A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development","volume":"41","author":"Di","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0091270006298359","article-title":"Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice","volume":"47","author":"Farkas","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6446(05)03681-0","article-title":"Role of pharmacologically active metabolites in drug discovery and development","volume":"11","author":"Fura","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.115.068601_bib16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0090-9556(25)07487-2","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib19","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1111\/j.1365-2125.1983.tb02270.x","article-title":"Pharmacokinetics and bioavailability of midazolam in man","volume":"16","author":"Heizmann","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib20","first-page":"2220","article-title":"Excretion and metabolism of 14C-midazolam in humans following oral dosing","volume":"31","author":"Heizmann","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.115.068601_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0163-7258(81)90056-5","article-title":"Drug metabolite kinetics","volume":"15","author":"Houston","year":"1981","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/dmd.111.042994","article-title":"Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data","volume":"40","author":"Jones","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1248\/yakushi.130.1325","article-title":"Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development","volume":"130","author":"Kang","year":"2010","journal-title":"Yakugaku Zasshi"},{"key":"10.1124\/dmd.115.068601_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","article-title":"Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/dmd.107.019539","article-title":"Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans","volume":"36","author":"Klieber","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2125.2002.01588.x","article-title":"Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers","volume":"53","author":"Knoester","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","article-title":"Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping","volume":"66","author":"Link","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.111.042200","article-title":"Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole","volume":"40","author":"Lutz","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokmetic-pharmacodynamic modeling of the central nervous system effects of midazolarn and its main metabolite hvdroxvmidazolarn in healthy volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","article-title":"Midazolam: a review of therapeutic uses and toxicity","volume":"15","author":"Nordt","year":"1997","journal-title":"J Emerg Med"},{"key":"10.1124\/dmd.115.068601_bib35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/156802611794480873","article-title":"Predicting clearance in humans from in vitro data","volume":"11","author":"Obach","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.115.068601_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/pr.111.005439","article-title":"Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy","volume":"65","author":"Obach","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.115.068601_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib39","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.068601_bib40","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-9556(25)07996-6","article-title":"A commentary: methods and assumptions in the kinetic estimation of metabolite formation","volume":"11","author":"Pang","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF01060018","article-title":"Sequential first-pass elimination of a metabolite derived from a precursor","volume":"7","author":"Pang","year":"1979","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.115.068601_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF01059690","volume":"5","author":"Pang","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.115.068601_bib44","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.115.068601_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib47","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib48","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1124\/dmd.109.027656","article-title":"Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters","volume":"37","author":"Rowland","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib49","series-title":"Clinical Pharmacokinetics\/Pharmacodynamics","author":"Rowland","year":"2005"},{"key":"10.1124\/dmd.115.068601_bib50","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib51","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/tx0602012","article-title":"Metabolites and safety: What are the concerns, and how should we address them?","volume":"19","author":"Smith","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.115.068601_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00562804","article-title":"The pharmacokinetics of midazolam in man","volume":"19","author":"Smith","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068601_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.068601_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i03","article-title":"Inverse modelling, sensitivity and monte carlo analysis in R using package FME","volume":"33","author":"Soetaert","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1124\/dmd.115.068601_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib57","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.115.064303","article-title":"Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters-enzyme interplay and the role of circulating metabolite gemfibrozil 1-O-\u03b2-glucuronide","volume":"43","author":"Varma","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib58","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068601_bib59","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068601_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.115.068601_bib61","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.clpt.2004.07.001","article-title":"Cytochrome P450 3A expression and activity in the human small intestine","volume":"76","author":"Yang","year":"2004","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624100712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624100712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.115.068601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:19:56Z","timestamp":1739888396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624100712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0090955624100712"],"URL":"https:\/\/doi.org\/10.1124\/dmd.115.068601","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.115.068601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}